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1Division of Public Health Sciences and the Alvin J. Siteman Cancer Center, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, United
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Why Study Trichomonosis and Prostate Cancer?
Trichomonosis, a sexually transmitted infection (STI) caused by
the protist Trichomonas vaginalis, has significant public health
relevance. The annual incidence is ,8 million women in the
United States and 170 million worldwide, with an equal number of
infected male partners [1]. Both men and women infected with T.
vaginalis are at increased risk for human immunodeficiency virus
infection [1]. Recent evidence suggests this STI is associated with
increased risk of prostate cancer, the most commonly diagnosed
cancer and the second leading cause of cancer death among men
in the United States [2]. There is no immunity to T. vaginalis, and a
hallmark of this STI agent is persistence. Most T. vaginalis
infections in men are asymptomatic, and few are diagnosed and
treated; thus, infections persist. In older, pre-antibiotic era studies,
T. vaginalis was frequently found in prostate fluid specimens from
asymptomatic male partners of women with trichomonosis,
leading to the belief that the prostate might serve as the reservoir
for trichomonosis in men [3]. Trichomonosis may cause chronic
prostatitis, and researchers have identified trichomonads in the
prostatic urethra, glandular lumina, submucosa, and stroma [4]
and, more recently, in benign hyperplastic prostatic tissue [3].
They also observed foci of nonspecific acute and chronic
inflammation, as well as intraepithelial vacuolization, near tri-
chomonads, leading them to propose that trichomonosis might
contribute to prostate carcinogenesis [4].
What Epidemiologic Evidence Links Trichomono-
sis to Prostate Cancer?
The a-actinin protein is one of the most immunogenic proteins
of T. vaginalis. This protein is not found among other microor-
ganisms and shares little amino acid sequence identity with its
human homolog. Among Tritrichomonas suis, Candida albicans, and
Saccharomyces cerevisiae, this protein has only 4.8%, 9.8%, and 11.1%
overall identities, respectively. H. sapiens homologs of a-actinin
have only 25% overall identity. Further, we performed epitope
mapping using as probes representative sera of T. vaginalis–infected
female and male patients that were highly reactive to both whole
cell T. vaginalis and a-actinin by ELISAs [5–7]. Surprisingly, the
female sera reacted with 13 epitopes scattered throughout the
entire a-actinin protein, whereas male sera detected only 5
epitopes that were identical to a subset of those recognized by the
female sera. These epitopes have no identity to other proteins in
databanks. This indicates that the female and male antibody
responses to a-actinin are polyclonal and recognize multiple
epitopes. There is no detection using these female and male sera,
singly or in combination, with purified human a-actinin protein.
Therefore, a highly seropositive reaction to this protein in humans
indicates exposure to T. vaginalis.
Recently, in a number of independent studies, trichomonosis
history, as measured by serum antibodies against T. vaginalis a-
actinin protein, was found to be associated with prostate cancer
risk. In a large nested case-control study within the Health
Professionals Follow-up Study, a positive relation between T.
vaginalis serostatus and prostate cancer risk was found [6]. This
association was slightly stronger for high-grade disease. This study
was followed by analyzing two additional populations, the Prostate
Cancer Prevention Trial (PCPT) [7] and the Physicians’ Health
Study (PHS) [5]. While the PCPT study did not observe an
association, the PHS study detected significant positive associa-
tions for extraprostatic and fatal prostate cancer [5]. It was noted
that the PCPT null findings may have been due to the very early
stage of prostate cancer examined in the trial. Finally, as further
epidemiologic evidence for an association between trichomonosis
and prostate cancer risk, African Americans, who have the highest
incidence of trichomonosis [1], also have the highest risks of
prostate cancer diagnosis and death [2]. Thus, an accumulating
body of evidence suggests that trichomonosis contributes to
prostate carcinogenesis, a particularly more aggressive or fatal
disease.
What Is a Possible Molecular Mechanism for T.
vaginalis–Mediated Prostate Carcinogenesis?
Despite the observed relation between T. vaginalis seropositivity
and prostate cancer risk, there is a dearth of knowledge regarding
how this parasite might contribute to prostate carcinogenesis. We
propose two synergistic molecular mechanisms. First, we hypoth-
esize that T. vaginalis infection may contribute to carcinogenesis via
inflammation, which is believed to be important for prostate
cancer development [8]. Second, we hypothesize and present
preliminary data and published reports that T. vaginalis adherence
or binding of specific trichomonad adhesin proteins to normal
prostate epithelial cells (PECs) triggers a cell-signaling cascade
through known proto-oncogenes, PIM1, c-MYC, and HMGA1, that
may ultimately lead to prostate carcinogenesis [9–12].
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Does T. vaginalis Mediate Inflammation?
T. vaginalis infection is characterized by cytopathogenicity, and
an influx of leukocytes and chronic inflammation [1]. Parasite
adherence to vaginal epithelial cells (VECs) induces expression of
monocyte chemoattractant protein-1 and IL-8, pro-inflammatory
cytokines involved in neutrophil recruitment [13]. High levels of
IL-8, leukotreine B4, and neutrophils have been found in vaginal
secretions from patients with trichomonosis [14]. Neutrophils may
contribute to carcinogenesis by secreting a variety of oxygen- and
nitrogen-based reactive molecules capable of damaging DNA and
nearby cells [15]. T. vaginalis attachment to VECs has also been
shown to lead to elevated levels of IL-6 [16], a key inflammatory
mediator associated with worse prostate cancer presentation/
prognosis [17] and with prostate cancer incidence and mortality
among healthy-weight men in a large prospective study [18]. More
recently, we have shown that parasite contact with PECs induces
expression of IL-6 (unpublished data). The key point is that T.
vaginalis infection promotes synthesis of pro-inflammatory cyto-
kines that may be important in prostate carcinogenesis.
What of the PIM1-HMGA1-COX2 Cell-Signaling
Cascade?
PIM1
The PIM1 gene is a known proto-oncogene [19] whose encoded
protein belongs to a small family of serine/threonine kinases that
are unique because they are constitutively active. PIM1 is believed
to be important for carcinogenesis because expression of this gene
can lead to genomic instability and the preservation of potentially
cancer-producing genomic alterations by promoting cell survival
under conditions in which these alterations would not be normally
tolerated [20]. PIM1 may be important for prostate cancer, in
particular because altered levels of PIM1 were observed in a study
comparing malignant-to-benign prostate specimens by gene
expression microarray and clinically stratified prostate cancer
specimens by protein arrays [15], as well as in studies comparing
malignant-to-benign prostate specimens and studies of prostate
cancer tissue and cell lines using immuno-histochemistry with
antibody to PIM1 [11]. Of particular relevance for T. vaginalis
infection, we have demonstrated that T. vaginalis contact leads to
increased PIM1 expression in PECs (see below and Figure 1),
providing a possible molecular mechanism by which T. vaginalis
contributes to prostate carcinogenesis. Importantly, it has been
demonstrated that PIM1 gene expression is induced by IL-6 via
the JAK/STAT signaling pathway [21] and that T. vaginalis–
induced IL-6 likely provides an additional molecular link between
exposure of human PECs to T. vaginalis, stress, and cancer
induction.
HMGA1
The proto-oncogeneHMGA1 encodes a chromatin ‘‘architectural
transcription factor’’ [22] that, evidence indicates, acts downstream
of PIM1 in an HMGA1-mediated prostate cancer induction
pathway (Figure 2). Phosphorylation of c-MYC by the PIM1 kinase
has been shown to induce binding of a PIM1/c-MYC complex to
the E box in the promoter of c-MYC target genes, such as HMGA1,
and induce their transcription [23]. Both c-MYC and HMGA1
have also been found to be over-expressed in prostate cancers,
suggesting the importance of the PIM1/c-MYC/HMGA1 signaling
cascade in prostate carcinogenesis. Further evidence supporting a
role for HMGA1 in prostate carcinogenesis includes the observation
that high levels of HMGA1 in prostate cancer cells are related to
enhanced proliferation and metastasis in vivo, studies suggesting
that HMGA1 is involved in prostate cell chromosomal instability
and rearrangements, and the fact that HMGA1 regulates
transcription of a number of genes involved in various aspects of
cell transformation and metastatic tumor progression. For example,
the Prostate-Specific Membrane Antigen (PSMA) gene promoter
has binding sites for HMGA1, and experiments have shown that
transcription of both the human STAT3 [24] and COX-2 [25] genes
are regulated in vivo by binding of the HMGA1 protein to their
promoter regions. The oncogenic effects of HMGA1may be further
amplified because activation of the STAT3 gene promoter by
HMGA1 (Figure 2, dashed line) may potentially lead to a chronic
self-reinforcing ‘‘feed-back’’ stimulatory loop resulting in constitu-
tively high levels of HMGA1 expression. As for PIM1, HMGA1
may also be important for T. vaginalis–mediated prostate carcino-
genesis as part of the PIM1Rc-MYCRHMGA1 signaling cascade
because we have recently demonstrated that T. vaginalis contact up-
regulates expression of HMGA1 in PECs (Figure 1). HMGA1
transcription is also known to be induced by cell stress and IL-6-
mediated inflammation, possibly providing a further mechanism by
which T. vaginalis may contribute to prostate carcinogenesis. As we
have also shown that T. vaginalis induces IL-6 in PECs (unpublished
data), we hypothesize that this stimulation is, likewise, due to the
downstream binding of HMGA1 to the IL-6 promoter that has
binding sites for the protein, thereby providing increased IL-6
expression, which can then reinforce the cascade and contribute to
prostate cancer progression by a separate, related mechanism.
Figure 1. Demonstration of elevated amounts of PIM1 and
HMGA1 proteins in PECs after adherence by T. vaginalis (Tv). In
this experiment, trichomonads were added to T25 confluent monolay-
ers of PECs (lane labeled+) using a parasite to PEC ratio of 10:1. PECs
without added organisms are labeled with a minus sign (2). This ratio
of 10:1 was chosen because it has been shown to yield at least one
parasite attached per epithelial cell in adherence assays and to
optimally signal epithelial cells for up-regulation of expression of genes
[13,27]. After visible attachment to PECs, non-adherent organisms were
decanted and fresh PEC medium added followed by incubation at 37uC
for an additional 30 min. The flask was then placed directly in ice for
detachment of organisms, after which PECs were washed and removed
from the flask for preparation of total proteins for immunoblotting
using established protocols, polyclonal rabbit antibodies produced in
our laboratories, and equal loading of protein onto gels, as detailed
previously [28]. Under conditions of exposure of PECs with or without T.
vaginalis, no change in the amount of other cellular proteins was
detected, as evidenced by no changes in the amounts of Akt and Bad,
and this served to show equal amounts of total proteins loaded onto
gels for SDS-PAGE and immunoblotting [28]. Prebleed rabbit serum was
used as the negative control and gave no reactivity.
doi:10.1371/journal.ppat.1002801.g001
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COX-2
We believe that COX-2 may be involved in T. vaginalis–
mediated prostate carcinogenesis because we have recently shown
that COX-2 expression is induced in primary human VECs upon
interaction with either intact T. vaginalis or purified trichomonad
adhesin AP65 [13]. Further, HMGA1 up-regulates expression of
COX-2 [25], and COX-2 over-expression in prostate cancer has
been documented and associated with both cancer initiation and
progression. Like HMGA1, COX-2 over-expression has also been
demonstrated in many other cancers, including breast, colorectal,
head and neck, esophageal and non-small-cell lung cancers, and
prostatic hyperplasia. COX-2 may play a role in cancer initiation
and progression by affecting cell proliferation, mitosis, cell
adhesion, apoptosis and immune surveillance, and/or angiogen-
esis. Interestingly, polyamines also regulate levels of COX-2 in
human airway epithelial cells [26], and T. vaginalis secrete large
amounts of polyamines (putrescine) during growth [27]. Poly-
amines play a role in cell cycle regulation in various types of
cancers. The secreted polyamines, in concert with the induced
host genes, might alter cell cycle regulation and result in a
proliferative phenotype. Thus, transcriptional activation of the
HMGA1 proto-oncogene promotes prostate cancer progression via
pathways that involve both COX2 and PSMA.
In summary, although several epidemiologic studies have
observed positive associations between T. vaginalis seropositivity
and prostate cancer risk, a major knowledge gap exists in
understanding how T. vaginalis activates signal transduction
pathways known to be associated with prostate carcinogenesis.
We present testable hypotheses and a working model (Figure 2)
supported by evidence [19] and believe that future research should
investigate these novel findings at the molecular level.
References
1. Hobbs MM, Sena AC, Swygard H, Schwebke JR. (2008) Trichomonas vaginalis
and trichomoniasis. In: Holmes KK, Sparling PF, Stamm WE, Piot P,
Wasserheit JN, Corey L, Cohen MS, Watts DH, editors. Sexually transmitted
diseases. New York: McGraw-Hill Medical. pp. 771–793.
2. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA
Cancer J Clin 62: 10–29.
3. Mitteregger D, Aberle SW, Makristathis A, Walochnik J, Brozek W, et al. (2012)
High detection rate of Trichomonas vaginalis in benign hyperplastic prostatic tissue.
Med Microbiol Immunol 201: 113–116.
4. Gardner WA, Culberson DE, Bennett BD (1986) Trichomonas vaginalis in the
prostate gland. Arch Pathol Lab Med 110: 430–432.
5. Stark JR, Judson G, Alderete JF, Mundodi V, Kucknoor A, et al. (2009)
Trichomonas vaginalis infection and prostate cancer incidence and mortality:
a prospective study in the physician’s health study. J Natl Cancer Inst 101:
1–6.
6. Sutcliffe S, Giovannucci E, Alderete JF, Chang TH, Gaydos, et al. (2006) Plasma
antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer.
Cancer Epidemiol Biomarkers Prev 15: 939–945.
Figure 2. A working model of how chronic, latent T. vaginalis infection of prostate tissue up-regulates the signaling cascade leading
to prostate carcinogenesis. Production of IL-6 leads to transcriptional activation of the STAT3-PIM1-HMGA1 cascade. In this case induced
transcriptional activation of the HMGA1 proto-oncogene contributes directly to prostate cancer progression via pathways involving COX2 and the
prostate-specific membrane antigen. The inset shows a T. vaginalis organism adherent to a VEC, and the same mechanism of cytoadherence occurs
for PECs.
doi:10.1371/journal.ppat.1002801.g002
PLoS Pathogens | www.plospathogens.org 3 August 2012 | Volume 8 | Issue 8 | e1002801
7. Sutcliffe S, Alderete JF, Till C, Goodman PJ, Hsing AW, et al. (2009)
Trichomonosis and subsequent risk of prostate cancer in the Prostate Cancer
Prevention Trial. Intl J Cancer 124: 2082–2087.
8. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, et al. (2007)
Inflammation in prostate carcinogenesis. Nature Rev Cancer 7: 256–269.
9. Diana F, Di Bernardo J, Sgarra R, Tessari MA, Rustighi A, et al. (2005)
Differential HMGA expression and post-translational modifications in prostate
tumor cells. Int J Oncol 26: 515–520.
10. Shah N, Pang B, Yeoh KG, Thorn S, Chen CS, et al. (2008) Potential roles for
the PIM1 kinase in human cancer—a molecular and therapeutic appraisal.
Eur J Cancer. 44: 2144–2151.
11. Valdman A, Fang X, Pang ST, Ekman P Egevad L (2004) PIM1 expression in
prostatic intraepithelial neoplasia and human prostate cancer. Prostate 60: 367–
371.
12. Wang J, Kim J, Franco OE, Hayward SW, Wills ML, et al. (2010) Pim1 kinase
synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene 29:
2477–2487.
13. Kucknoor AS, Mundodi V, Alderete JF (2007) The proteins secreted by
Trichomonas vaginalis and vaginal epithelial cell response to secreted and
episomally expressed AP65. Cell Microbiol 9: 2586–2597.
14. Ryu JS, Kang JH, Jung SY, Shin MH, Kim JM, et al. (2004) Production of
interleukin-8 by human neutrophils stimulated with Trichomonas vaginalis. Infect
Immun 72: 1326–1332.
15. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, et al. (2001)
Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822–826.
16. Han IH, Park SJ, Ahn MH, Ryu JS (2012) Involvement of mast cells in
inflammation induced by Trichomonas vaginalis via crosstalk with vaginal epithelial
cells. Parasite Immunol 34: 8–14.
17. Azevedo A, Cunha V, Teixeira AL, Medeiros R (2011) IL-6/IL6R as a potential
key signaling pathway in prostate cancer development. World J Clin Oncol 2:
384–396.
18. Stark, JR, Li H, Kraft P, Giovannucci EL, Stampfer M, et al. (2009a)
Circulating prediagnostic interleukin-6 and C-reactive protein and prostate
cancer incidence and mortality. Int J Cancer 124: 2683–2689.
19. Magnuson NS, Wang Z, Ding G, Reeves R (2010) Why target PIM1 for cancer
diagnosis and treatment? Future Oncol 6: 1461–1478.
20. Roh M, Franco OE, Hayward SW, van der Meer R, Abdulkadir SA (2008) A
role for polyploidy in the tumorigenicity of PIM1-expressing human prostate and
mammary epithelial cells. PLoS ONE 3: e2572. doi:10.1371/journal.-
pone.0002572
21. Sansone P, Bromberg J (2012) Targeting the interleukin-6/jak/stat pathway in
human malignancies. J Clin Oncol 30: 1005–1014.
22. Reeves R, Beckerbauer L (2001) HMGI/Y proteins: flexible regulators of
transcription and chromatin structure. Biochim Biophys Acta 1519: 13–29.
23. Zhang Y, Wang Z, Li X, Magnuson NS (2008) Pim-1 kinase-dependent
inhibition of c-MYC degradation. Oncogene 27: 4809–4819.
24. Hillion J, Dhara S, Sumter TF, Mukherjee M, Di Cello F, et al. (2008) The high-
mobility group A1a/signal transducer and activator of transcription-3 axis: an
Achilles heel for hematopoietic malignancies? Cancer Res 68: 10121–10127.
25. Tesfaye A, Di Cello F, Hillion J, Ronnett BM, Elbahloul O, et al. (2007) The
high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in
uterine tumorigenesis. Cancer Res 67: 3998–4004.
26. Cowan MJ, Coll T, Shelhamer JH (2006) Polyamine-mediated reduction in
human airway epithelial migration in response to wounding is PGE2 dependent
through decreases in COX-2 and cPLA2 protein levels. J Appl Physiol 101:
1127–1135.
27. Garcia A, Benchimol M, Alderete JF (2005) Trichomonas vaginalis polyamine
metabolism is linked to host cell adherence and cytotoxicity. Infect Immun 73:
2602–2610.
28. Hu XF, Li J, Vandervalk S, Wang Z, Magnuson NS, et al. (2009) PIM-1-specific
mAb suppresses human and mouse tumor growth by decreasing PIM1 levels,
reducing Akt phosphorylation, and activating apoptosis. J Clin Invest 119: 362–
375.
PLoS Pathogens | www.plospathogens.org 4 August 2012 | Volume 8 | Issue 8 | e1002801
